Addressing the calculation of patent term extensions (PTEs) under the Hatch-Waxman Act, the US Court of Appeals for the Federal Circuit affirmed ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Reporting zero taxable profits in the U.S. in 2019, Pfizer (NYSE:PFE) carried out possibly the largest tax-avoidance scheme ...

The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Ea Bridgeway Blue Chip ETF's valuation is attractive, with a P/E ratio 12.5% below the S&P 500, driven by its sector ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

Merck & Co. is flexing its dividend muscles with 14 years of consecutive growth and a yield that's juicier than a ripe ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Merck & Co. has won approval from the European Commission of its Capvaxive pneumococcal disease vaccine for adults. The Rahway, N.J., drugmaker on Wednesday said the approval covers the 21-valent ...